Physician profile
Syed Ali
NPI 1952338998
$1,812.51
in general payments reported to CMS, 2019-2025
18 companies · $169 in 2025
The $169 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $61.78 · 2021: $122 · 2022: $422 · 2023: $428 · 2024: $365 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $953 · Education: $8.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $953.28 |
| Education | $8.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $388.33 | 2020-2025 | Vafseo, Auryxia |
| Astrazeneca Pharmaceuticals LP | $278.55 | 2019-2023 | Lokelma, Farxiga |
| Amgen INC. | $227.39 | 2023-2024 | Tavneos |
| Fresenius USA Marketing, INC. | $201.98 | 2019-2025 | Velphoro, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $198.22 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $73.00 | 2024-2025 | |
| Travere Therapeutics, INC. | $67.47 | 2022-2024 | |
| Horizon Therapeutics Plc | $65.41 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $61.08 | 2019-2024 | Ultomiris |
| Vifor Pharma, INC. | $52.97 | 2022-2023 | Korsuva, Veltassa |
| Otsuka America Pharmaceutical, INC. | $43.44 | 2021-2022 | |
| Ardelyx, INC. | $40.30 | 2023-2024 | Ibsrela |
| Lundbeck LLC | $33.90 | 2024-2025 | Rexulti |
| Genzyme Corporation | $18.34 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.60 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $17.54 | 2021 | |
| Calliditas Therapeutics US INC. | $14.64 | 2025 | Tarpeyo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $12.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.